MTAAFF
Market cap187mUSD
Dec 23, Last price
7.44EUR
1D
0.81%
1Q
-12.47%
Jan 2017
-19.72%
IPO
-20.94%
Name
Fine Foods & Pharmaceuticals NTM SpA
Chart & Performance
Profile
Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract development and manufacturing of oral solid forms for the pharmaceutical and nutraceutical industries. It offers pharmaceutical products, including powders and granules, capsules, tablets, film-coated tablets, effervescent granules, and hard gelatine capsules. The company also provides nutraceutical products comprising soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, fast melting/sublingual tablets, film-coated tablets, and hard gelatin capsules for various therapeutic areas, such as probiotics, multivitamins and minerals, immune systems, sleep and relax, gastrointestinal system, circulatory system, osteoarticular system, urinary system, women health, beauty, healthy ageing, and mental wellbeing. In addition, the company manufactures and trades in cosmetics products consisting of hair care, skin care, liquid detergents for personal hygiene, skin care emulsions, oral hygiene, deodorants, alcohol-based perfumery, bath and shower gel, shampoo and conditioners, shaping waxes, mouthwash and breath products, creams, gel and toothpaste, roll-on, stick and vapo spray deodrants, intimate cleansers, emulsions and microemulsions, gels, and liquid soaps; medical surgical aids and medical devices; antiseptics for undamaged skin, hand gel, pre-injection, hydroalcoholic surfaces, and iodine; and orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. The company was founded in 1984 and is headquartered in Verdellino, Italy.
IPO date
Oct 19, 2016
Employees
Domiciled in
IT
Incorporated in
IT
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
Income | ||||||||
Revenues | 251,812 21.73% | 206,853 6.39% | 194,424 12.36% | |||||
Cost of revenue | 186,206 | 177,920 | 157,266 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 65,606 | 28,933 | 37,157 | |||||
NOPBT Margin | 26.05% | 13.99% | 19.11% | |||||
Operating Taxes | 1,667 | (4,698) | (3,164) | |||||
Tax Rate | 2.54% | |||||||
NOPAT | 63,939 | 33,631 | 40,321 | |||||
Net income | (3,522) -62.93% | (9,501) 565.93% | (1,427) -110.68% | |||||
Dividends | (2,453) | (3,867) | (3,206) | |||||
Dividend yield | 1.11% | 1.89% | 0.87% | |||||
Proceeds from repurchase of equity | (341) | (7,012) | ||||||
BB yield | 0.15% | 1.90% | ||||||
Debt | ||||||||
Debt current | 55,624 | 40,565 | 69,006 | |||||
Long-term debt | 12,154 | 82,670 | 45,671 | |||||
Deferred revenue | (241) | (1,081) | ||||||
Other long-term liabilities | 2,204 | 2,701 | 4,127 | |||||
Net debt | 48,624 | 46,490 | 19,586 | |||||
Cash flow | ||||||||
Cash from operating activities | 18,538 | 3,688 | (5,827) | |||||
CAPEX | (18,126) | (15,984) | (15,920) | |||||
Cash from investing activities | 45,888 | (15,315) | (36,348) | |||||
Cash from financing activities | (55,658) | 4,740 | 55,951 | |||||
FCF | 60,560 | 24,471 | (10,534) | |||||
Balance | ||||||||
Cash | 19,155 | 76,745 | 95,090 | |||||
Long term investments | ||||||||
Excess cash | 6,564 | 66,402 | 85,369 | |||||
Stockholders' equity | 31,772 | 30,485 | 74,987 | |||||
Invested Capital | 188,980 | 224,546 | 185,733 | |||||
ROIC | 30.92% | 16.39% | 25.80% | |||||
ROCE | 33.51% | 11.33% | 14.19% | |||||
EV | ||||||||
Common stock shares outstanding | 25,158 | 24,538 | 23,941 | |||||
Price | 8.77 5.16% | 8.34 -45.84% | 15.40 46.67% | |||||
Market cap | 220,634 7.81% | 204,646 -44.49% | 368,687 43.55% | |||||
EV | 269,258 | 251,136 | 388,274 | |||||
EBITDA | 82,409 | 44,405 | 50,559 | |||||
EV/EBITDA | 3.27 | 5.66 | 7.68 | |||||
Interest | 4,808 | 2,083 | 701 | |||||
Interest/NOPBT | 7.33% | 7.20% | 1.89% |